Terns Pharmaceuticals appoints Kerry Russell as Chief Medical Officer effective June 1, 2022

Terns Pharmaceuticals, Inc.

Kerry Russell, M.D., Ph.D., named CMO, reporting to President and Head of R&D Erin Quirk, M.D.
Dr. Russell previously VP of late clinical development at Dicerna Pharmaceuticals (acquired by Novo Nordisk).
She held leadership roles at resTORbio, Novartis, and was an NIH-funded associate professor at Yale.
Terns expects key clinical data readouts for TERN-501, TERN-601, and TERN-701 across NASH, obesity, and CML.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.